News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
BioCryst Pharma Sells European Business for Rare Disease Drug in $250M Deal - MedCity News
Neopharmed Gentili is acquiring European rights to Orladeyo, bringing the Italy-based pharmaceutical company into rare disease. BioCryst’s Orladeyo is approved for treating patients with the rare disease hereditary angioedema.
The $232 Billion Problem: The Price of Overlooking the Impact of Trauma in the U.S. - MedCity News
When we talk about post-traumatic stress disorder (PTSD), a condition fundamentally born from overwhelming experiences that leave a long-term imprint on the body, our mainstream approach often feels stuck in the past.
No Wrong Door: How Policy, Technology & Partnerships Can Power a Connected Social Safety Net - MedCity News
Through the convergence of proactive policy, advanced technology and strategic public-private partnerships, we can achieve this “no wrong door” vision and deliver a connected, streamlined social safety net that’s more efficient, economical, and effective. Here’s how.
Why Hospitals Must Rethink Operations Before Banking on AI - MedCity News
Some hospitals are turning to AI to help manage declining revenue and financial pressure, but one expert says success depends on more than just buying new tech. Prashant Karamchandani of Chartis urges health systems to pair AI adoption with foundational work like change management, continuous improvement and operating model redesign.
Data Technology + RWD Are Positive for Rare Disease Treatment - MedCity News
Technology that offers tools that conform, de-identify, link and aggregate data and data science tools like AI, machine learning and advanced analytics, can help those researching rare diseases overcome the hurdles they face in discovery and development.
How Healthcare Leaders Are Responding to the Supreme Court’s Preventive Care Ruling - MedCity News
The Supreme Court upheld the constitutionality of an Affordable Care Act provision requiring insurance coverage of certain preventive services without cost-sharing. Many healthcare leaders applauded the decision, though some concerns remain.
Who is Speaking About AI at MedCity INVEST Digital Health in Dallas? - MedCity News
The conference will explore ethical considerations for AI in healthcare, how the healthcare industry is managing the teething challenges of AI "hallucinations", practical concerns such as efficacy and ROI, and more. Register today!
Innovative Strategies to Enhance Financial Predictability for Self-Funded Employers - MedCity News
Too often, the very systems meant to provide flexibility and control are undermined by delayed reimbursements, fragmented data, and a lack of transparency across the ecosystem. Solving this isn’t about tweaking the status quo, it requires a full redesign.
FDA Just Made Some Key Regulatory Changes to Make Cancer Cell Therapies More Accessible - MedCity News
The FDA has eliminated a safety monitoring requirement and eased certain restrictions that had been in place since CAR T-therapies first reached the market in 2017. The agency and financial analysts say the changes should improve patient access to these personalized cancer treatments.
From Burnout to Breakthrough: Reinventing Pediatric Care for the Next Generation - MedCity News
There is no singular cause to pediatrician burnout. Rather, it’s a web of interconnected issues, compounded and feeding upon each other. And if we want to truly support pediatricians and the children they care for, we need to stop treating symptoms and start untangling the root causes.
Vor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in Funding - MedCity News
Vor Bio is licensing global rights a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder generalized myasthenia gravis. It’s a pivot for Vor, which last month ceased its cancer R&D and announced it would explore strategic alternatives.
Beyond Technology: Aligning AI Tools with Systemic Change in Healthcare - MedCity News
The widespread investment in AI furthers economists’ optimism about a “roaring 20’s” of worker productivity on the horizon. However, this will not take place in health care without accompanying systemic and organizational actions that rethink what we financially incentivize, how we integrate new technologies, how we shift tasks, and how we prepare the workforce.
How More Competition and Better Connected Data Will Solve Healthcare's Billion Dollar Problem - MedCity News
There are two changes that could transform the entire system. If we can do these two things, the entire market improves. Not everyone will win, but the good products, the good distributors and the good platforms will rise to the top.
Novavax Sees Sanofi Vaccine Pact as Model for Future Deals, Some Going Beyond Infectious Disease - MedCity News
Novavax’s partnership with Sanofi allows the pharma giant to explore potential combinations of assets from both companies, and it’s a blueprint for the kinds of alliances the vaccine developer is pursuing. Rather than commercializing vaccines, Novavax aims to turn its research into business development deals, R&D executive Ruxandra Draghia-Akli said.
Nektar’s Novel Eczema Drug Meets Trial Goals, But Differentiation From Dupixent Remains Unclear - MedCity News
Nektar Therapeutics’ biologic drug rezpegaldesleukin take a new approach to atopic dermatitis, or eczema, stimulating proliferation of immune cells that tamp down excessive immune responses. The drug met the goals of a Phase 2b study, but analysts note that cross-trial measures show those results are short of the marks achieved by Dupixent, the top biologic for atopic dermatitis.
How Smarter Metrics Can Unlock AI’s Potential in Healthcare - MedCity News
Healthcare doesn’t reward shortcuts. It rewards outcomes. AI will play a critical role in shaping those outcomes — but only if leaders measure what truly matters. The best AI implementations elevate expertise, improve quality and create space for innovation.
The Hospital Word Has Become a Tale of the Haves and Have-Nots - MedCity News
Health system performance has splintered into three distinct groups — leaders, strugglers and those stuck in the middle, according to Fitch Ratings’ Kevin Holloran. At the HFMA Annual Conference, he and Mayo Clinic CFO Dennis Dahlen discussed how technology and innovation are accelerating this divide.
The Medicaid Reckoning: Era of Fiscal and Policy Flux - MedCity News
The resilience of Medicaid lies in its complexity. It has resisted large-scale restructuring because it is interwoven with public and private delivery systems. That same complexity now demands a different kind of legal engagement. Medicaid is no longer a silo, but a system-defining platform.
Vertex Pharma’s Type 1 Diabetes Cell Therapy Shows Potential to Achieve Insulin Independence - MedCity News
In Phase 1/2 results for 12 patients at least one year after receiving the cell therapy, zimislecel, Vertex Pharmaceuticals reported all participants achieved blood glucose in the target range and 10 of the 12 were free of exogenous insulin as of the data cutoff. Vertex expects to complete enrollment in the pivotal portion of the study this summer, paving the way for potential regulatory submissions next year.
Why This Former OpenAI Exec Is Urging Health Leaders to ‘Specialize in Empathy’ - MedCity News
At the HFMA Annual Conference, AI expert Zack Kass shared a personal story to emphasize the enduring importance of human qualities like empathy and compassion in healthcare. In his view, these qualities will only become more essential as AI continues to transform the clinical landscape.
Why Intermountain Health Is Investing In AI for Clinical Data Abstraction - MedCity News
Intermountain Health is deploying Layer Health’s AI engine for clinical data abstraction across several of its patient registries. The health system’s venture capital arm is also making a strategic investment in the startup.
What OpenAI’s o3 Price Drop Means for the Future of AI in Healthcare? - MedCity News
To be clear, this doesn't mean healthcare organizations should adopt LLMs tomorrow. But what’s changed is that the primary obstacle - cost at scale - is no longer the immovable obstacle it once was. For healthcare leaders who have been watching the AI wave from the sidelines, this is the moment to move from curiosity to action.
Precision Medicine Firm Caris Breaks Bio IPO Drought, Raising $494M for Cancer Analysis Tools - MedCity News
Caris Life Sciences applies AI and machine learning to patient samples to detect cancer and as a companion diagnostic guiding the use of targeted cancer therapies. As a commercial-stage company, Caris’s upsized public markets debut is an outlier amid the continuing IPO freeze for clinical-stage biotechs developing new drugs.